CSF2 and breast carcinoma: Last, given that G-CSF and GM-CSF are routinely administered to prevent neutropenia in patients with breast cancer undergoing chemotherapy, a closer look at the immunosuppressive impacts of these cytokines, particularly in a setting of minimal residual disease, is warranted.